Information and calculation tools by Rachid Asen. Not investment advice or research.

Disclaimer. Information tool. Compiles data published by NSE and BSE and calculations from the exchanges' published ESM and ASM criteria. Prices are end-of-day, not live: updated each evening after trading ends. Ethical business criteria are matched by AI, which can make mistakes; this is a criteria match, not a certification, fatwa, rating or advice. Check the company's filings. Not investment advice, research or a recommendation to buy, sell or hold any security; not SEBI-registered as an Investment Adviser or Research Analyst. Calculated dates are the earliest a security could become eligible; inclusion, stage changes and exit are decided solely by the exchanges. ESM, ASM and GSM shortlisting are surveillance measures and not an adverse action against the company. Data may be delayed or inaccurate; verify with the exchange.

AlphaSurveillanceby Rachid AsenNotebookDiscussionConnect AISign in
Market closedIST

Symbiotec Pharmalab Limited

SYMBIOTEC (NSE) · SYMBIOTEC (BSE 544889) · ISIN INE899I01028 · Pharmaceuticals · Est. 2002 · listed 2026 · website

Not on any surveillance list

In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹210.84 cr and profit after tax ₹47.01 cr.

Next: Board meeting: financial results on 5 November 2026.

Quarterly results

Quarterly results, ₹ crore (as filed)
QuarterRevenueProfit after taxEPS (₹)Filed
Q1 FY27 standalone₹210.84 cr₹47.01 cr7.4921 Sep 2026

Shareholding

Shareholding pattern, Sep 2026
PromoterFIIDIIPublic
33.28%3.79%33.17%66.72%

Latest filings

Other companies in Pharmaceuticals

Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.

Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.